Here's Why Bristol Myers Offered MyoKardia $13.1 Billion
Cardiovascular drugs have been unsuccessful investments in recent years, but this one makes sense.
Full Article
Here's Why Bristol Myers Offered MyoKardia $13.1 Billion
Motley Fool
0 shares
1 views
You might like
Related news coverage
-
With buyout of MyoKardia, Bristol-Myers Squibb reaches into heart of Bay Area biotech
bizjournals
-
Regeneron, MyoKardia rise; DraftKings, AMC fall
SeattlePI.com
-
US stocks rebound as investors bet on renewed hopes for stimulus deal
Proactive Investors
-
Bristol Myers Squibb Begins a $13.1 Billion Purchase of MyoKardia
Motley Fool
Advertisement
More coverage
Bristol Myers to acquire MyoKardia for £10 billion
Invezz
In an announcement on Monday, Bristol Myers Squibb Co (NYSE: BMY) said it will invest £10 billion to acquire MyoKardia Inc..
-
US stocks higher and FTSE 100 closes up as sentiment is boosted on US stimulus package hopes
Proactive Investors
-
Stock Alert: MyoKardia Surges 60% On Bristol Myers Acquisition
RTTNews
-
US benchmarks race out of the blocks Monday on reports of President Trump's health and stimulus package hopes
Proactive Investors
-
Bristol Myers Snaps Up MyoKardia For $225/Share
RTTNews